Table 1 Characteristics and outcomes of 162 SARS-CoV-2 hospitalized patients, according to need of intensive care

Age, median (IQR)

64.4 (50.4–74.2)

62.6 (49.8–74.8)

64.8 (54.7–72.1)

Males, n (%)

99 (61.1)

68 (56.2)

31 (75.6)

Symptom duration before hospitalization, median days (IQR)^a

7.6 (4.6–11.5)

7.5 (4.1–10.9)

9.2 (6.6–13.3)

Length of stay, median days (IQR)

7.7 (4.1–12.3)

6.0 (4.0–9.9)

14.5 (9.5–28.1)

Mechanical ventilation, n (%)

34 (21.0)

-

34 (82.9)

Extracorporeal membrane oxygenation (ECMO), n (%)

2 (1.2)

-

2 (4.9)

Antibiotic or antifungal treatment

71 (43.8)

35 (28.9)

36 (87.8)

Mortality, n (%)

17 (10.5)

9 (7.4)

8 (19.5)

Community-acquired infections, n patients (%)

6 (3.7)

4 (3.3)

2 (4.9)

 Viral co-infection, n events (%)

5 (3.1)

4 (3.3)

1 (2.4)

 Bacterial pneumonia and bacteraemia, n events (%)

1 (0.6)

0

1 (2.4)

Hospital-acquired infections, n patients (%)

 17 (10.5)

2 (1.7)

15 (36.6)

 Bacterial and/or fungal infection, n events (%)

25 (15.4)

2 (1.7)

23 (56.1)

 Bacterial infection, n events (%)

23 (13.6)

2 (1.7)

21 (51.2)

  -Ventilator-associated pneumonia (VAP) ^{b, c}

5 (3.1)

0

5 (12.2)

  -Tracheobronchitis ^c

13 (8.0)

0

13 (31.7)

  -Non-ventilator-associated pneumonia

1 (0.6)

1 (0.8)

0

  -Hospital-acquired bacteraemia

4 (2.5)

1 (0.8)

3 (7.3)

 Fungal infection, n events (%)

3 (1.9)

0

3 (7.3)

  -Ventilator-associated pneumonia (VAP) ^{b, c}

2 (1.2)

-

2 (4.9)

  -Hospital-acquired candidemia

1 (0.6)

-

1 (2.4)